Cori Gorman, PhD, MBA
DNA Bridges

Presentation Abstract

The SBIR grant program can provide a significant source of funding to help get new companies started and achieve their corporate goals. You need a view of the various agencies and programs to see which is the best fit for your project. Chances of success can vary but a strategic plan can help you increase your chances. Remember the SBIR program goal is commercialization; it is not meant to support 'just' cool science. We recommend that you start thinking about a commercialization plan early, even though Phase I is needed to tested the feasibility of your idea. This will be key to how you present your overall goal for the project. Remember, your strategy must consider the opportunity cost and a source of the real money and business during and after SBIR.

Biographical Sketch

Cori Gorman, Ph.D., MBA, of DNA Bridges, Inc. is an expert in gene expression and protein production as well as gene transfer including gene therapy. She has first hand knowledge about the review process for federal grants having served on an SBIR review committee at the NIH for over five years. In addition to being a successful PI on five SBIR grants, she has coached others in grant writing so that they have also been successful in obtaining funds in the millions. Cori has worked at Genentech, was a founder of Valentis, a gene therapy company, and is one of the most highly cited scientists in the past two decades with more than 10,000 citations.

Her company, DNA Bridges, Inc. provides expert consulting and professional services to the life sciences, biotechnology, pharmaceutical and diagnostic industries. Strategic and operational solutions are based on more than 30 years' experience in industry. Experienced in: gene expression, recombinant protein production, patent portfolio management, cell culture manufacturing, clinical diagnostics and strategic planning to assist you in bridging science to products

Return to the Funding Fair Frontpage